Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Professor Tim Spector has issued an urgent warning to people who may wish to take Ozempic "without a medical need". Ozempic ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. Shares were 9.5% higher ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Oprah Winfrey has been slammed for her controversial comments about 'thin people' while discussing her use of weight loss ...

Oprah Winfrey shares her transformative weight-loss journey with GLP-1 medications, challenging societal perceptions of willpower and obesity in a candid podcast conversation with Dr. Ania Jastreboff.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Body positivity is shifting with the rise of weight-loss drugs and a booming skincare industry. Discover how body neutrality offers a healthier approach.